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Abstract: 
The field of NASH therapeutics has recently witnessed a dramatic increase in clinical trials. In 
this review, we discuss emerging promising compounds that have demonstrated positive effects 
on NASH histology in completed phase II randomized controlled trials (RCT). These compounds 
include obeticholic acid (OCA), Elafibranor, and liraglutide. OCA and Elafibranor have now 
moved to be tested in ongoing large phase III RCTs. These RCTs are slated to provide the 
largest efficacy and safety data in NASH therapeutic trials to date and will also collect hard 
clinical outcomes. The data from the completed Cenicrivorc phase II RCT is expected in the 
next year, which may provide impetus for yet another large phase III RCT. Based on promising 
results from a small phase II study, there are now two ongoing large phase III trials are 
assessing the efficacy of Selonsertib in NASH patients with bridging fibrosis or cirrhosis. 
Ultimately, demonstration of long term efficacy, tolerability and safety will be essential for these 
and other agents in the pipeline. 
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Key points: 
- There is a dramatic increase in the number of clinical trial testing various compounds 
that target different important molecules and pathways in NASH pathogenies 
- Obeticholic acid, Elafibranor, and liraglutide have demonstrated variable beneficial 
effects on NASH histology in phase II randomized controlled trials. 
- The 1 year, mid-study interim analysis of Cenicrivorc’s phase IIb study showed an 
encouraging improvement in hepatic fibrosis. Completed results after an addition 1 year 
of therapy are expected later this year. 
- Exciting results from phase II study of Selonsertib provided impetus for two large 
ongoing phase III trials to assess the efficacy of Selonsertib in NASH patients with 
bridging fibrosis or cirrhosis 
- Cysteamine Bitartrate and Long-chain polyunsaturated fatty acids did not achieve the 
primary endpoint of histological improvement in high quality phase II randomized 
controlled trials. 
 
 
 
 
 
 
 
 
 
 
 
 
Synopsis: 
This review will discuss completed phase II randomized clinical trials with high quality published 
results for compounds that demonstrate effects on NASH histology (Obeticholic acid, 
Elafibranor and Liraglutide). We will also review the available preliminary data on Cenicrivorc,  
and Selonsertib-with or without Simtuzumab’s phase II studies. Finally, we will briefly discuss 
compounds that have been tested but did not achieve the primary endpoint of histological 
improvement and appeared in high quality published papers (Cysteamine Bitartrate and Long-
chain polyunsaturated fatty acids). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The public health burden of NAFLD is now widely recognized. NAFLD is the most common liver 
disease in children and adults in the US [1-3]. End stage liver disease and hepatocellular 
carcinoma secondary to NAFLD are now the second leading indications for liver transplantation 
in the US, an alarming trend that is expected to culminate in NAFLD replacing hepatitis C as the 
most common indication for liver transplantation in the next decade [4-6]. 
 
The rise of prevalence and importance has been paralleled by better understanding of NAFLD 
pathophysiology (reviewed in details in Chapter 7 in this issue). Numerous molecules and 
pathways driving the progression of NAFLD are currently the targets of emerging therapies. The 
intense interest in finding treatments for NAFLD and NASH is best highlighted by the dramatic 
increase in registered phase II and III clinical trials for NAFLD and NASH over the past 10 years 
(Figure. 1). 
 
Goals of NAFLD and NASH therapy include improving or stabilizing liver histological injury and 
fibrosis, prevention of liver-related poor outcomes and death, and improving or not worsening 
associated cardio-metabolic comorbidities.   With the many pathways and molecules involved in 
NAFLD-NASH pathogenesis, it is likely that a combination of drugs targeting different molecules 
and pathways may be used in the future to achieve these goals. Because therapy for NAFLD 
and NASH is probably going to be chronic, drugs used will not only need to be efficacious, but 
also have a favorable profile on safety, tolerance and cardio-metabolic comorbidities.  
 
Current treatments of NAFLD and NASH are discussed in details in Chapter.13. In this chapter, 
we will review completed phase II randomized controlled trials (RCTs) with high quality 
published positive results (Table. 1). We will also review the available preliminary data on 
Cenicrivorc and Selonsertib-with or without Simtuzumab’s phase II studies which have 
histological end points (Table.2). Finally, we will touch on compounds that have been tested and 
failed to meet the primary endpoint of histological improvement and had high quality published 
papers. 
 
I. Promising emerging drugs from completed phase II RCTs 
 
Obeticholic acid (OCA) 
As an agonist of the bile acid nuclear receptor farnesoid X receptor (FXR), OCA regulates of 
bile acids synthesis and transport and modulates lipid and glucose homeostasis and hepatic 
inflammation [7, 8].   
 
The efficacy of OCA in treating NASH was tested in FLINT (Farnesoid X Receptor Ligand 
Obeticholic acid In NASH Treatment) [9]. In this trial,  283 subjects with histologically confirmed 
NASH but without cirrhosis were randomized to receive OCA 25 mg orally daily or matching 
placebo for 72 weeks. Type 2 diabetes was present in 53% of the OCA and 52% of the control 
groups. The primary outcome was a decrease in NAFLD fibrosis score (NAS) by at least 2 
points without worsening of fibrosis from baseline to the end of treatment.  A planned interim 
analysis showed significant improvement in liver histology in subjects receiving OCA which led 
to modifying the study protocol and not pursuing end of treatment liver biopsy on the last 64 
subjects. In an intention to treat analysis, 45% of subjects in the OCA group versus 21% in the 
placebo group achieved the study primary outcome (relative risk 1.9, 95% CI 1.3 to 2.8; 
p=0·0002). OCA was also associated with significant improvement in fibrosis (35% vs 19%, 
p=0·004), hepatocyte ballooning (46% vs 31%, p=0·03), steatosis (61% vs 38%, p=0·001), and 
lobular inflammation (53% vs 35%, p=0·006). There was no significant difference in the 
frequency of NASH resolution with OCA vs placebo (22% vs 13%, p=0.08). 
 
OCA was associated with significant reduction in ALT (-38 vs -18 U/L, p<0·0001), AST ( -27 vs -
10 U/L, p=0·0001), GGT ( -37 vs -6, p<0・0001) and bilirubin (-1.0 vs 0.6 µmol/L, p=0.002) but 
increase in alkaline phosphatase ( 12 vs -6, p<0・0001). These changes resolved 24 weeks after 
study drug cessation, at which point, no significant difference in liver biochemistries were noted 
between those on OCA vs placebo.  
 
Subjects on OCA experienced significant weight loss compared to placebo (-2.3 vs 0.0 kg, 
p=0·008), higher insulin (29 vs 10 pmol/L, p=0.02) and HOMA-IR (15 vs 4, p=0.01). Significant 
changes in serum lipoproteins were also observed with OCA vs placebo: increase in total 
cholesterol (0.16 vs -0.19 mmol/L, p=0·0009), LDL (0.22 vs -0.22 mmol/L, p<0·0001) and a 
decrease in HDL (-0.02 vs 0.03 mmol/L, p=0.01). These changes attenuated while on drug but 
were not sustained after completion of the study.  
 
OCA therapy was associated with pruritus in 23% of subjects vs 6% of those on placebo. 
Pruritus was also more severe with OCA and lead to stopping OCA in one subject and using 
antipruritic therapies and holding OCA briefly in other subjects .  
 
There were 5 severe or life-threatening adverse events that were thought to be related to OCA. 
These include severe pruritus (n=3), hyperglycemia (n=1), and possible cerebral ischemia 
(n=1). This compared to 4 severe or life-threatening adverse events in subjects on placebo 
(abdominal pain, headache, weakness, vertigo with nausea and vomiting). Two deaths occurred 
during the study duration; one from congestive heart failure and sepsis and one from myocardial 
ischemia or infarction both in subjects receiving OCA but were deemed not to be related to 
OCA.  
 
Subsequently, a large phase III RCT of OCA has been launched (NCT02548351).  A target of 
2000 subjects with biopsy proven NASH will be randomized to OCA 10 mg daily, OCA 25 mg 
daily, or matching placebo for 18 months. The primary endpoints are 1) reduction in fibrosis 
without worsening of NASH, 2) resolution of NASH and 3) all-cause mortality and liver-related 
clinical outcomes spanning 6 years from the start of the study.  This study is currently recruiting 
in centers around the world.  
 
Elafibranor 
Elafibranor (GFT505) is a dual agonist of the nuclear peroxisome proliferator activated receptors 
(PPAR)-α and δ. It has been shown to improve insulin sensitivity, lipid handling and 
inflammation [10, 11]. Elafibranor improved liver histology in different animal models of NASH 
[11-13].  
 
In a large phase II RCT, 276 subjects with biopsy proven NASH without cirrhosis were 
randomized to receive Elafibranor 80 mg vs Elafibranor 120 mg vs placebo for 52 weeks. In the 
intention to treat group, 40% had type 2 diabetes. NASH resolution without worsening of fibrosis 
was the primary end point. This was not achieved as there was no significant different in the 
primary end point between the three study groups. There was no significant effect for either 
dose of Elafibranor on steatosis, lobular inflammation or hepatocyte ballooning in the primary 
analysis. A post-hoc analysis was then performed looking at patients with NASH and NAS ≥4, 
which showed that in this subgroup, Elafibranor 120 mg resulted in higher proportion of NASH 
resolution vs placebo (20% vs 11%; odds ratio=3.16; 95% confidence interval: 1.22-8.13; 
p=0.018), in addition to improving steatosis, ballooning, lobular inflammation, and NAS by 2 
points. There was no effect for Elfibranor on fibrosis in the primary analysis. In the post-hoc 
analysis, those with NAS≥4 who received the 120 mg dose and had NASH resolution showed 
significant improvement in fibrosis as well as other histological features compared to those on 
the same dose without NASH resolution. 
 
Patients receiving either dose of Elafibranor had significant improvement in liver enzymes, 
lipoproteins, triglycerides and circulating markers of inflammation (haptoglobin and fibrinogen). 
There was significant improvement in HOMA-IR fasting glucose level and hemoglobin A1c only 
in diabetic subjects in the Elafibranor 120 mg arm.  
 
No cardiovascular events or deaths occurred in subjects receiving Elafibranor. There was no 
effect on body weight. Mild increase in serum creatinine was noted in the Elafibranor arms in 7 
subjects (6 in the 120 mg arm) who had elevated creatinine and decreased glomerular filtration 
rate at baseline which led to discontinuation of the drug with subsequent improvement in 
creatinine in most but not all subjects.  Serious adverse events occurred in 15 (16.1%), patients 
in the 80-mg, and 14 (15.8%) patients in the 120-mg and 11 (12%) patients in the placebo 
arms. There were 8 treatment-related serious adverse events: 2 in the 80-mg Elafibranor group 
(spontaneous abortion, ataxia, fasciculation, and tremor), in 2 in the Elafibranor 120 mg group 
(acute pancreatitis, Parkinson disease), and in 4 patients from the placebo arm (renal cancer, 
breast cancer, bladder cancer, and pancreatic cancer): In addition, one bladder cancer occurred 
in the elafibranor 80-mg arm. All cancers were assessed to be unlikely related to study drug. 
 
There is currently an ongoing phase III RCT of Elafibranor (NCT02704403) in patients with 
biopsy proven NASH without cirrhosis. The target enrollment is 2000 subjects who will be 
randomized to Elafibranor 120 mg vs placebo for 72 weeks. Resolution of NASH without 
worsening of fibrosis as well as clinical outcomes (all cause death and liver related events over 
4 year period) will be the primary outcome measures. 
 
Liraglutide 
Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue that is used for glycemic control in 
patients with type 2 diabetes. GLP-1 has many biological effects that make it an attractive option 
to treat NASH. It reduces glucagon secretion, increases insulin secretion, suppresses hepatic 
de novo lipogenesis, increases fatty acid oxidation and delays gastric emptying. These effects 
result in insulin sensitivity and weight loss [14]. Preliminary human data suggested the GLP-1 
analogues may improve liver histology in patients with NASH [15, 16]. 
 
More recently, a phase II RCT examined the effects of Liraglutide on biopsy proven NASH [17]. 
The LEAN trial (Liraglutide Efficacy and Action in Non-alcoholic steatohepatitis) randomized 52 
patients with histologically proven NASH to receive either 1.8 mg/day of Liraglutide 
subcutaneously or placebo for 48 weeks. Subjects with type 2 diabetes and compensated 
cirrhosis were not excluded from the study. Similar proportion of patients with type 2 diabetes 
were included in the Liraglutide group vs placebo (35% vs 32%), but lower proportion of 
subjects on Liraglutide had advanced hepatic fibrosis (Kleiner stage 3 and 4) (46% vs 58%) and 
cirrhosis (8% vs 15%) compared to placebo. The primary endpoint of this trial was resolution of 
NASH with no worsening of fibrosis at the end of the study. More subjects receiving Liraglutide 
achieved the primary end point compared to placebo (39% vs 9% relative risk 4∙3 [95% CI 1∙0–
17∙7]; p=0∙019).  Improvement of steatosis was more common on Liraglutide (83% vs 45%, 
p=0.009) and worsening of fibrosis was less frequent on Liraglutide (9% vs 36%, p=0.04) 
(Figure.2). No significant differences were noted in the frequency of improvement in NAS or 
lobular inflammation but the improvement of hepatocyte ballooning showed a trend towards 
significance on Liraglutide (61% vs 32%, p=0.05).  
 
 
There was significant improvement in hemoglobin A1c and HDL on Liraglutide. There was a 
numeric but non-statistically significant improvement in ALT, AST, and keratin-18 on Liraglutide. 
Importantly, there was more weight loss in subject on Liraglutide vs placebo (-5.5 kg vs -0.6 kg, 
p=0.003).  
 
Gastrointestinal side effects (e.g. nausea, diarrhea, abdominal pain, loss of appetite, etc...) were 
most common in both study arms (81% in Liraglutide arm vs 65% in placebo arm) and more 
common in the Liraglutide arm than controls. Constipation occurred in 27% of subjects on 
Liraglutide but in none of the subjects on placebo. There were 2 severe adverse events 
(tuberculosis and migraine) in the Liraglutide arm that were deemed not related to study drug. 
The drug withdrawal rate was similar between the 2 groups (19%). 
 
To our knowledge, there is no registered phase III RCT for Liraglutide in in NASH. 
 
II. Drugs in phase II studies with biopsy end points 
 
Cenicriviroc 
The chemokines CCL2 and CCL5 play an important role in macrophage recruitment and 
migration to the liver and are overexpressed in livers of obese patients with NASH [18]. 
Cenicriviroc is an oral antagonist of C-C chemokine receptors (CCR) 2 and 5. In animal models 
of different liver diseases, Cenicriviroc exhibited anti-inflammatory and anti-fibrotic effects [19]. 
 
The preliminary 1 year results of a phase IIb RCT (CENTAUR) were recently presented at the 
2016 liver meeting [20].  In this trial, 289 subjects with biopsy proven NASH were randomized to 
receive Cenicrivoric 150 mg daily vs placebo for 2 years. In total, 52% had type 2 diabetes, 72% 
metabolic syndrome and 67% stage 2-3 fibrosis. The primary outcome is ≥ 2 points 
improvement in NAS and secondary endpoints include complete resolution of steatohepatitis 
without worsening of fibrosis, and improvement in hepatic fibrosis by ≥1 stage. In this mid-study 
interim analysis, the proportion of subjects achieving the primary end point was not different 
between the two groups (16% vs 19% for Cenicriviroc vs placebo, p=0.5) , however, 20% of 
subjects on Cenicriviroc  achieved improvement in fibrosis by ≥1 stage without worsening of 
steatohepatitis compared to 10% of those on placebo (p=0.023) (Table.2). Treatment emergent 
adverse events of Grade ≥2 severity at a frequency ≥2% included fatigue (2.8%) and diarrhea 
(2.1%) for Cenicriviroc , and headache (3.5%) for placebo.  
 
These are exciting results and the final effects of Cenicriviroc on liver histology at the end of the 
trial (an additional 1 year of therapy), are awaited. 
 
Selonsertib and Simtuzumab 
Inhibition of Apoptosis Signal-Regulating Kinase (ASK1) in mice and monkeys with diet induced 
NAFLD results in improvement in hepatic fibrosis, inflammation, steatosis, and insulin sensitivity 
[21, 22]. Selonsertib (GS-4997) is a selective oral inhibitor of ASK1. In a recent randomized 
phase II clinical trial, Selonsertib’s safety and efficacy in human NASH were tested in 
combination with Simtuzumab, an injectable humanized monoclonal antibody to LOX like-2 
which exhibits anti-fibrotic effects [23, 24].  
 
In this study, 72 subjects with histologically proven NASH with NAS ≥ 5 and stage 2-3 fibrosis 
were randomized to receive Selonsertib 6 mg or 18 mg orally once daily, with or without 
Simtuzumab 125 mg subcutaneously once weekly, or just Simtuzumab 125 mg subcutaneously 
once weekly for 24 weeks. Diabetes was present in 70.8% of all subjects. All subjects had a 
repeat biopsy at the end of study. In addition, fibrosis and fat were assessed by MR-
elastography (MRE) and proton density fat fraction (MR-PDFF) at baseline, 12 weeks and end 
of study. Fibrosis improvement by ≥1 stage and progression to cirrhosis were the primary 
histological efficacy end points, whereas ≥15% reduction in MRE measured liver stiffness and ≥ 
30% reduction in MR=PDFF measured hepatic fat were the MR-based efficacy end points. 
Fibrosis improvement by ≥1 stage without worsening of steatohepatitis was observed in 37%, 
30%, and 20% whereas progression to cirrhosis was observed in 3%, 7%, and 20%, in the 
Selonsertib 18 mg (±Simtuzumab), Selonsertib 6 mg (±Simtuzumab), vs Simtuzumab alone 
groups, respectively (Table 2). MRE-stiffness reduction≥ 15% was noted in 20%, 32% and 0% 
whereas MR-PDFF fat reduction ≥30% was noted in 26%, 13%, and 10% in the Selonsertib 18 
mg (±Simtuzumab), Selonsertib 6 mg (±Simtuzumab), vs Simtuzumab alone groups, 
respectively. Stability or improvement in NAS and lobular inflammation, and reduction of fibrosis 
as measured by morphometric hepatic collagen per 1% decrease and MRE stiffness per 1-kPa 
decrease, were associated with improvement in pathologist’s assessment of fibrosis. No deaths 
occurred during the study. Five serious adverse events were reported in the Selonsertib ± 
Simtuzumab groups vs none in the Simtuzumab group, with only 1 serious adverse event 
deemed related to study drug. Treatment was discontinued to adverse events in 3 subjects 
(4.8%) Selonsertib ± Simtuzumab groups vs none in the Simtuzumab group.  
 
The safety and efficacy of Selonsertib vs placebo is currently being tested in two phase III RCTs 
in adults with bridging fibrosis (STELLAR 3, NCT03053050) or compensated cirrhosis 
(STELLAR 4, NCT03053063) due to NASH.  Each study plans to recruit 800 subjects and study 
duration will be 240 weeks. Two phase II clinical trials in patients with NASH and bridging 
fibrosis (NCT01672866) or cirrhosis (NCT01672879) evaluating intravenous simtuzumab’s 
efficacy and safety have been terminated. 
 
 
III. Drugs that have been tested in phase II trials without achieving primary histological 
end point 
 
Cysteamine Bitartrate 
As a precursor to glutathione, Cysteamine has the advantage of crossing of cellular membranes 
more efficiently than glutathione. Its efficacy at protecting against acetaminophen-induced liver 
injury has been demonstrated in prior studies in humans [25, 26].  
 
A recent RCT in 169 children with NAFLD activity scores ≥4 (CyNCh; Cysteamine bitartrate 
delayed-release for the treatment of Nonalcoholic fatty liver disease in Children) randomized 
subjects to receive weight-based Cysteamine or placebo twice daily for 52 weeks [27]. A 
decrease in NAS ≥2 points without worsening fibrosis was the primary outcome. Despite a 
significant improvement in liver enzymes (ALT -53 ± 88 U/L vs -8 ± 77 U/L; p = 0.02, AST-31 ± 
52 vs -4 ± 36 U/L; p = 0.008), and lobular inflammation (36% vs 21%; p = 0.03) on Cysteamine 
compared to placebo, the primary end point was not achieved. In subgroup analyses, children 
younger than 13 years showed histological improvement with Cysteamine [43% (16/37) vs 21% 
(8/39), relative risk, 2.3; 95% CI, 1.0–5.2; p=0.04). Children weighing ≤65 kg also showed 
histologic improvement and achieved the primary outcome on cysteamine vs placebo [observed 
in 50% (12/24) vs 13%(3/23); relative risk, 4.0; 95% CI, 1.3-12.3; p=0.005], which was due to 
improvement in lobular inflammation (54% vs 22%, relative risk, 2.6; 95% CI,  (1.1–6.0); p=0 
.02) and hepatocyte ballooning (33% vs 4%, relative risk, 8.3;  95% CI, 1.0–71.3; p=0.01).  
 
Validation of the effects of Cysteamine on NASH histology per age and weight will require 
adequately powered RCT to measure any potential effect. To our knowledge, there is currently 
no registered future clinical trial for Cysteamine.  
 
 Long-chain polyunsaturated fatty acids (LC-PUFAs) 
LC-PUFAs are abundant in fish and fish oil supplements and exhibit beneficial metabolic and 
anti-inflammatory effects, including improvement in insulin sensitivity and reduction in serum 
triglycerides, endothelial dysfunction and adipose tissue inflammation [28-30].  
 
Earlier reports of favorable effects on liver enzymes and hepatic steatosis with LC-PUFAs were 
not substantiated by larger phase II RCTs [31-34].  One RCT randomized 103 subjects with 
NAFLD to receive docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (4 gm/day) 
for 15-18 months [35]. There was no significant change in hepatic steatosis or non-invasive 
markers of fibrosis at the end of the study. The largest RCT of LC-PUFAs randomized 243 
subjects with histologically confirmed NASH to receive EPA 1800 mg/day, EPA 2700 mg/day, or 
placebo for 12 months [36]. Subjects on EPA showed no significant change in liver enzymes, 
markers of fibrosis, insulin resistance or liver histology compared to those on placebo.  This 
data suggests that LC-PUFAs are not an effective therapy for NASH.  
 
 
Conclusions 
The intense interest in NASH therapeutics has translated in a significant increase in clinical 
trials. Of the emerging promising compounds, OCA, Elafibranor, and liraglutide have evidence 
from phase II RCT of variable beneficial effects on NASH histology. Exciting preliminary results 
from a small phase II study, have led to the launch of two large phase III trials to assessing the 
efficacy of Selonsertib in NASH patients with bridging fibrosis or cirrhosis.  OCA and Elafibranor 
have now moved to be tested in ongoing large phase III RCTs. These RCTs are slated to 
provide the largest efficacy and safety data in NASH therapeutic trials to date and will also 
collect hard clinical outcomes. The data from the completed Cenicrivorc phase II RCT is 
expected in the next year, which may provide impetus for yet another large phase III RCT. For 
all these promising compounds and others in different stages of development, establishment of 
long term safety, efficacy and tolerability will be key for their approvals as therapies for patients 
with NASH. 
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Figure. 1. Registered phase II and III clinical trials for NAFLD-NASH from 2006-2016*.  
 
 
* Search of clnicaltrials.gov as of 2/8/17 for NAFLD | Interventional Studies | Phase II, III | 
Studies received from 01/01/2006 to 01/01/2017. 
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Figure.2. Results of the LEAN trial.  
 
 
* : p<0.05, #: p=0.05, remaining comparisons p> 0.05. 
LI: Lobular inflammation, NAS: NAFLD Activity Score. 
 
 
 
 
  
Table.1 Summary of drugs with published phase II trials with evidence of effect on NASH histology. 
Drug Mechanism Study size  
(n) 
Route of 
administration 
Effect on histology Common side effects 
Obeticholic acid FXR agonist 283 Oral  Improvement in NAS, 
steatosis, ballooning, 
lobular inflammation and 
fibrosis 
Pruritus 
Weight loss 
Temporary increase in alkaline 
phosphatase 
Temporary changes in lipoprotein profile 
Elafibranor PPAR-α and 
δ agonist 
276 Oral In subjects with NAS ≥4, 
Elafibranor 120 mg 
resulted in higher 
proportion of NASH 
resolution, improved 
ballooning, lobular 
inflammation, and NAS by 
2 points.  
No significant effect on 
steatosis or fibrosis. 
 
Mild increase in serum creatinine in 7.1% 
of subjects on Elafibranor 120 mg. 
Liraglutide GLP-1 
analogue 
52 Subcutaneous Resolution of NASH with 
no worsening of fibrosis. 
Improved steatosis 
Gastrointestinal symptoms 
Weight loss 
 
 
 
 
 
 
 
Table. 2 Summary of preliminary studies of anti-fibrotic agents, Cenicrivoric and Selonsertib-
Simtuzumab 
 Cenicrivoric Selonsertib 18 mg (±Simtuzumab),  
Selonsertib 6 mg (±Simtuzumab),  
Simtuzumab alone 
Mechanism Antagonist of C-C chemokine 
receptors 2 and 5 
Inhibitor of ASK1 (Selonsertib) 
Humanized monoclonal antibody to LOX like 2 
(Simtuzumab) 
Route of administration Oral Oral (Selonsertib) 
Subcutaneous (Simtuzumab) 
Size of initial study 289 72 
Diabetics included Yes Yes  
% Improvement in fibrosis ≥ 1 stage 
without worsening of steatohepatitis 
20 37, 30, 20 
Interval Histological effect observed 1 year 6 months 
Ongoing clinical trials Current IIb with 289 subjects for 
2 years 
2 ongoing phase III trials  
Selonsertib vs placebo 
(NASH with bridging fibrosis or cirrhosis), each 
with 800 subjects for 240 weeks 
*Note these are separate studies with preliminary results, not head to head comparisons 
between the agents. 
